在疹脑炎中使用阿西克洛维尔剂量:一个范围审查
Journal of the American Pharmacists Association : JAPhA
|February 16, 2024
概括
对于患有疹脑炎的肥胖患者来说,确定正确的阿西克洛维尔剂量是具有挑战性的. 本次审查强调需要进一步研究,以建立最佳的剂量策略,并防止不良影响或无效治疗.
科学领域:
- * 神经学 神经学
- * 传染病 传染病
- * 药理学 药理学 药理学
背景情况:
- *疹脑炎是一种严重的病毒感染,仅用阿西克洛维尔治疗.
- *目前的阿西克洛维尔剂量指南 (10毫克/千克/每8小时一次的静脉注射剂量) 对肥胖患者来说不清楚.
- *对肥胖个体的错误剂量可能会导致次治疗水平或毒性 (毒性/神经毒性).
研究的目的:
- *对在肥胖的疹脑炎患者中服用阿西克洛维尔的现有证据进行范围审查.
主要方法:
- *全面的数据库搜索 (MEDLINE,EMBASE,Scopus,科学网,CINAHL) 于2023年5月26日进行.
- * 两位独立审稿人使用Covidence软件对文章进行选和选择.
- * 在综述中包含22篇文章.
主要成果:
- * 乙克洛维尔相关的毒性患病率在13%至21%之间;神经毒性数据未定义.
- * 缺乏关于与亚治疗性阿西克洛维尔度相关的结果的证据.
- *建议的方法:使用调整体重的肥胖患者与正常的功能;考虑最大剂量的人增加清除.
结论:
- * 关于在肥胖患者中计算阿西克洛维尔剂量的适当体重存在重大不一致.
- *建议进行进一步的研究,以比较肥胖患者与非肥胖患者的阿西克洛维尔度.
- *未来的研究应该将阿西克洛维尔度与患者的结果相关联,以完善剂量指南.
相关概念视频
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
301
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
301


